CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 84 enrolled
Drug / intervention
Blood Drawother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02812680
NCT02812680N/ACompleted
CompareCT.gov

The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma

University Health Network, Toronto·observational·Posted Jun 24, 2016·Updated Mar 8, 2024

In Brief

An observational study evaluating Blood Draw for Esophageal Cancer. Completed, enrolled 84 participants across 1 site.

Detailed Summary

Circulating microRNA (circ miRNA) and circulating tumor cell (CTC) levels are hypothesized to be associated with response to chemoradiation in patients undergoing treatment for locally advanced esophageal adenocarcinoma. The goal of this project is to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 24, 2016
Enrollment StartJun 1, 2016
Primary CompletionNov 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.0 years ago

Interventions

Blood Drawother

Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.